QLHC partners with pharmaceutical and biotechnology companies to advance drug and biomarker programs with our premier investigator network. The result: better evidence, generated sooner, in the patients most likely to benefit.
From protocol agreement to first subject enrolled — no delays waiting for infrastructure to catch up.
Consistent, high enrollment rates across our national site network, including 18 NCCN member institutions.
Simultaneous testing across multiple tumor biology subtypes provides a comprehensive picture of where your agent works.
Direct, iterative collaboration with the KOL network of investigators who shape how new therapies are used and understood.
The I-SPY Trials were designed to seamlessly advance novel therapeutics and therapeutic combinations to improve therapeutic response and decrease adverse events—all resulting in better patient care.
Getting started is straightforward. Reach out to our Collaborations team and we'll assess fit with our current platforms, connect you with the right investigators, and walk you through our streamlined arm design process. Every new arm is developed collaboratively, reviewed by two independent scientific committees, and executed across our 50+ site national network with weekly stakeholder touchpoints along the way.
The result is a process that is rigorous, transparent, and built around you — with the speed and scientific depth that only a purpose-built adaptive platform can deliver.
New clinical trial arms have advanced as quickly as 4 weeks from contract signature to first patient treated.
By investigators or your team.
Collaborations team, investigators, and partner work together.
I-SPY Agents Selection Committee approval.
Protocol and contract iterated to agreement.
QLHC executes contract, IRB, and IND amendment.
External expert committee approval.
Regulatory clearance coordinated by QLHC.
Sites activated across the national network.
Co-own your arm data and use it freely for commercialization. Competitor data stays protected — always.
Validate assays and train algorithms on matched specimens and longitudinal data from a uniquely well-characterized population.
De-identified, analysis-ready datasets and biospecimens to power translational science and biomarker programs.
Annotated biospecimens
Longitudinally collected
Longitudinally collected
WGS, WES, RNA-Seq
Neutral third-party intermediary
Independent sharing committee
Strict data use agreements
De-identified patient data
QLHC collaborates with leading clinical sites nationwide to expand patient access, accelerate enrollment, and advance groundbreaking research through adaptive trials. By joining our network, trial sites gain access to innovative protocols, collaborative scientific leadership, and a proven infrastructure designed to reduce operational friction and accelerate research. Together, we can help bring better treatment options to more patients.
